---
layout: post
title: "立方制药：收到原料药上市登记受理通知书"
date: 2022-04-28 19:31:20 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.003020" data-code="003020|0|2" data-code2="003020|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.003020&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 003020_0" data-code="K 003020|0|2" data-code2="K 003020|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>立方制药(003020)4月28日晚间公告，近日，公司收到国家药监局下发的丙胺卡因原料药上市登记申请《受理通知书》。丙胺卡因原料药上市登记申请获得受理，表示该品种进入注册审评阶段，对公司近期业绩不会产生影响。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204282364360963>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)